AP10-602

OTHER2 trials

Sponsors

National Institute of Allergy and Infectious Diseases (NIAID)

Conditions

Plasmodium Falciparum InfectionTuberculosis

Phase 1

Safety, Tolerability, and Immunogenicity of the Vaccine Candidates ID93 + AP10-602 and ID93 + GLA-SE Administered Intramuscularly in Healthy Adult Subjects

CompletedNCT02508376

National Institute of Allergy and Infectious Diseases (NIAID)Tuberculosis

Start: 2015-10-22End: 2017-08-31Updated: 2017-09-15

rCSP/AP10-602 [GLA-LSQ] Vaccine Trial

CompletedNCT03589794

National Institute of Allergy and Infectious Diseases (NIAID)Plasmodium Falciparum Infection

Start: 2018-12-21End: 2022-07-05Updated: 2023-07-10

Related Papers

Recombinant Full-length <i>Plasmodium falciparum</i> Circumsporozoite Protein–Based Vaccine Adjuvanted With Glucopyranosyl Lipid A–Liposome <i>Quillaja saponaria</i> 21: Results of Phase 1 Testing With Malaria Challenge

The Journal of Infectious Diseases2024-02-085 citations

Safety and immunogenicity of a thermostable ID93 + GLA-SE tuberculosis vaccine candidate in healthy adults.

2023-03-0623 citations

Low dose recombinant full-length circumsporozoite protein-based Plasmodium falciparum vaccine is well-tolerated and highly immunogenic in phase 1 first-in-human clinical testing.

2021-01-2215 citations